<?xml version='1.0' encoding='utf-8'?>
<document id="17958912"><sentence text="Are HIV positive patients resistant to statin therapy?" /><sentence text="Patients with HIV are subject to development of HIV metabolic syndrome characterized by dyslipidemia, lipodystrophy and insulin resistance secondary to highly active antiretroviral therapy (HAART)" /><sentence text=" Rosuvastatin is a highly potent HMG-CoA reductase inhibitor"><entity charOffset="1-13" id="DDI-PubMed.17958912.s3.e0" text="Rosuvastatin" /></sentence><sentence text=" Rosuvastatin is effective at lowering LDL and poses a low risk for drug-drug interaction as it does not share the same metabolic pathway as HAART drugs"><entity charOffset="1-13" id="DDI-PubMed.17958912.s4.e0" text="Rosuvastatin" /></sentence><sentence text=" This study sought to determine the efficacy of rosuvastatin on lipid parameters in HIV positive patients with HIV metabolic syndrome"><entity charOffset="48-60" id="DDI-PubMed.17958912.s5.e0" text="rosuvastatin" /></sentence><sentence text="" /><sentence text="Mean TC decreased from 6" /><sentence text="54 to 4" /><sentence text="89 mmol/L (25" /><sentence text="0% reduction, p &lt; 0" /><sentence text="001)" /><sentence text=" Mean LDL-C decreased from 3" /><sentence text="39 to 2" /><sentence text="24 mmol/L (30" /><sentence text="8% reduction, p &lt; 0" /><sentence text="001)" /><sentence text=" Mean HDL rose from 1" /><sentence text="04 to 1" /><sentence text="06 mmol/L (2" /><sentence text="0% increase, p = ns)" /><sentence text=" Mean triglycerides decreased from 5"><entity charOffset="6-19" id="DDI-PubMed.17958912.s21.e0" text="triglycerides" /></sentence><sentence text="26 to 3" /><sentence text="68 mmol/L (30" /><sentence text="1% reduction, p &lt; 0" /><sentence text="001)" /><sentence text=" Secondary analysis examining the effectiveness of rosuvastatin monotherapy (n = 70) vs"><entity charOffset="51-63" id="DDI-PubMed.17958912.s26.e0" text="rosuvastatin" /></sentence><sentence text=" rosuvastatin plus fenofibrate (n = 43) showed an improvement of 21" /><sentence text="3% in TG and a decrease of 4" /><sentence text="1% in HDL-C in the monotherapy group" /><sentence text=" The rosuvastatin plus fenofibrate showed a greater drop in triglycerides (45"><entity charOffset="60-73" id="DDI-PubMed.17958912.s30.e0" text="triglycerides" /></sentence><sentence text="3%, p &lt; 0" /><sentence text="001) and an increase in HDL of 7" /><sentence text="6% (p = 0" /><sentence text="08)" /><sentence text="" /><sentence text="This study found that rosuvastatin is effective at improving potentially atherogenic lipid parameters in HIV-positive patients"><entity charOffset="22-34" id="DDI-PubMed.17958912.s36.e0" text="rosuvastatin" /></sentence><sentence text=" The lipid changes we observed were of a smaller magnitude compared to non-HIV subjects" /><sentence text=" Our results are further supported by a small, pilot trial examining rosuvastatin effectiveness in HIV who reported similar median changes from baseline of -21"><entity charOffset="69-81" id="DDI-PubMed.17958912.s38.e0" text="rosuvastatin" /></sentence><sentence text="7% (TC), -22" /><sentence text="4% (LDL-C), -30" /><sentence text="1% (TG) with the exception of a 28" /><sentence text="5% median increase in HDL" /><sentence text=" In light of the results revealed by this pilot study, clinicians may want to consider a possible resistance to statin therapy when treating patients with HIV metabolic syndrome" /><sentence text="" /></document>